S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Modern Day Options Trading For Beginners! (Ad)pixel
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
The gold catalyst we’ve waited for (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
The gold catalyst we’ve waited for (Ad)
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Modern Day Options Trading For Beginners! (Ad)pixel
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
The gold catalyst we’ve waited for (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
The gold catalyst we’ve waited for (Ad)
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Modern Day Options Trading For Beginners! (Ad)pixel
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
The gold catalyst we’ve waited for (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
The gold catalyst we’ve waited for (Ad)
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Modern Day Options Trading For Beginners! (Ad)pixel
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
The gold catalyst we’ve waited for (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
The gold catalyst we’ve waited for (Ad)
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
NASDAQ:HUMA

Humacyte - HUMA Stock Forecast, Price & News

$3.24
+0.33 (+11.34%)
(As of 03/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.94
▼
$3.33
50-Day Range
$2.49
▼
$3.25
52-Week Range
$1.96
▼
$8.04
Volume
206,835 shs
Average Volume
253,120 shs
Market Capitalization
$334.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.58

Humacyte MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
152.7% Upside
$8.19 Price Target
Short Interest
Bearish
9.44% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.35mentions of Humacyte in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.96) to ($0.87) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.59 out of 5 stars

Medical Sector

802nd out of 995 stocks

Biological Products, Except Diagnostic Industry

139th out of 166 stocks

See Top Rated MarketRank™ Stocks Here

HUMA stock logo

About Humacyte (NASDAQ:HUMA) Stock

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Receive HUMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Humacyte and its competitors with MarketBeat's FREE daily newsletter.

HUMA Stock News Headlines

March 24, 2023 | finance.yahoo.com
Humacyte Announces Fourth Quarter and Year End 2022 Financial Results and Business Update
March 21, 2023 | finance.yahoo.com
Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 24, 2023
March 28, 2023 | Tradewins (Ad)
Modern Day Options Trading For Beginners!
These days it takes more than willpower to succeed on Wall Street and for new traders, even small mistakes can sink an account! With "Your Guide To Successful Options Trading" by expert Wendy Kirkland, you can avoid new trader pitfalls and learn to earn in this vicious market. pixel
March 7, 2023 | msn.com
Zymeworks Inc. (ZYME) Q4 Earnings and Revenues Beat Estimates
February 13, 2023 | sg.finance.yahoo.com
Humacyte, Inc. (HUMA)
February 10, 2023 | marketwatch.com
Bioprosthetics Market 2023 [New Report]: Qualitative Insights by Massive Growth and Share Forecast to 2028
January 30, 2023 | seekingalpha.com
Humacyte: With 2 BLAs Ahead, Solid Cash, Current Lows Make It Undervalued
January 24, 2023 | finance.yahoo.com
Humacyte Publication in the Journal of Vascular Surgery – Vascular Science Reports the Human Acellular Vessel™ (HAV™) Remains Durable at Six Years in Patients with Peripheral Artery Disease
March 28, 2023 | Tradewins (Ad)
Modern Day Options Trading For Beginners!
These days it takes more than willpower to succeed on Wall Street and for new traders, even small mistakes can sink an account! With "Your Guide To Successful Options Trading" by expert Wendy Kirkland, you can avoid new trader pitfalls and learn to earn in this vicious market. pixel
January 15, 2023 | finance.yahoo.com
Humacyte, Inc. (HUMA) Stock Historical Prices & Data - Yahoo Finance
December 13, 2022 | finance.yahoo.com
Humacyte Hosting Key Opinion Leader Webinar on Vascular Trauma: Ukrainian Surgeons Discuss Use of Human Acellular Vessels™ (HAV™) in Wartime
December 1, 2022 | finance.yahoo.com
Humacyte Human Acellular Vessel™ (HAV™) Ukraine Humanitarian Results to be Presented at Multiple Vascular Conferences in December 2022
November 23, 2022 | finance.yahoo.com
Humacyte to Present at the 34th Annual Piper Sandler Healthcare Conference
November 10, 2022 | finance.yahoo.com
Humacyte Third Quarter 2022 Financial Results and Business Update
November 7, 2022 | finance.yahoo.com
Humacyte Presents Six-Month Human Acellular Vessel™ (HAV™) Coronary Artery Bypass Graft (CABG) Data at the American Heart Association Scientific Sessions 2022 Meeting
November 3, 2022 | finance.yahoo.com
Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 10, 2022
October 13, 2022 | seekingalpha.com
Humacyte: Intriguing Potential (NASDAQ:HUMA) - Seeking Alpha
October 9, 2022 | fool.com
Humacyte, Inc. (NASDAQ: HUMA)
September 23, 2022 | globenewswire.com
Humacyte Announces Presentations by Ukrainian Surgeons on Use of the Human Acellular Vessel™ to Treat Wartime Vascular Trauma at the European Society for Vascular Surgery Annual Meeting - GlobeNewswire
September 23, 2022 | finance.yahoo.com
Humacyte, Inc.'s (NASDAQ:HUMA) last week's 12% decline must have disappointed individual investors who have a significant stake - Yahoo Finance
September 23, 2022 | bizjournals.com
2022 CEO of the Year & C-suite Awards: Laura Niklason – Humacyte - The Business Journals
September 23, 2022 | finance.yahoo.com
Humacyte Announces Presentations by Ukrainian Surgeons on Use of the Human Acellular Vessel™ to Treat Wartime Vascular Trauma at the European Society for Vascular Surgery Annual Meeting
September 20, 2022 | finance.yahoo.com
Humacyte Expands Board of Directors and Leadership Team with New Appointments - Yahoo Finance
September 20, 2022 | globenewswire.com
Humacyte Expands Board of Directors and Leadership Team with New Appointments - GlobeNewswire
September 20, 2022 | finance.yahoo.com
Humacyte Expands Board of Directors and Leadership Team with New Appointments
September 9, 2022 | finance.yahoo.com
Humacyte Announces Presentation on Investigational Human Acellular VesselTM for Treatment of Vascular Trauma at the International Committee of Military Medicine World Congress - Yahoo Finance
September 9, 2022 | streetinsider.com
Form N-CSRS Listed Funds Trust For: Jun 30 - StreetInsider.com
See More Headlines
Receive HUMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Humacyte and its competitors with MarketBeat's FREE daily newsletter.

HUMA Company Calendar

Today
3/28/2023
Next Earnings (Estimated)
5/12/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HUMA
CUSIP
N/A
CIK
1818382
Web
www.constellationalpha.com
Phone
919-313-9633
Fax
N/A
Employees
145
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.19
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$2.75
Forecasted Upside/Downside
+72.3%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.13)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-26,480,000.00
Net Margins
1,971.30%
Pretax Margin
1,970.90%
Return on Equity
-74.59%
Return on Assets
-35.49%

Debt

Debt-to-Equity Ratio
0.37
Current Ratio
9.75
Quick Ratio
9.75

Sales & Book Value

Annual Sales
$1.26 million
Price / Sales
265.17
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.19 per share
Price / Book
2.72

Miscellaneous

Outstanding Shares
103,120,000
Free Float
77,339,000
Market Cap
$334.11 million
Optionable
Optionable
Beta
1.22

Key Executives

  • Dr. Laura E. Niklason M.D. (Age 59)
    Ph.D., Founder, Pres, CEO & Director
    Comp: $783.36k
  • Mr. Dale A. Sander (Age 62)
    CFO, Chief Corp. Devel. Officer & Treasurer
    Comp: $12.5k
  • Dr. Heather Ledbetter Prichard Ph.D. (Age 44)
    Chief Operating Officer
    Comp: $576.44k
  • Dr. Juliana L. Blum Ph.D.
    Co-Founder & Exec. VP of Corp. Devel.
  • Ms. Sabrina Osborne
    Exec. VP of Bus. Strategy & People
  • Mr. William John Scheessele (Age 50)
    Chief Commercial Officer
  • Dr. Shamik J. Parikh M.D. (Age 49)
    Chief Medical Officer
  • Mr. Harold Alterson
    Sr. VP of Quality
  • Dr. Yang Cao M.D.
    Ph.D., Chief Regulatory Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













HUMA Stock - Frequently Asked Questions

Should I buy or sell Humacyte stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Humacyte in the last twelve months. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" HUMA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HUMA, but not buy additional shares or sell existing shares.
View HUMA analyst ratings or view top-rated stocks.

What is Humacyte's stock price forecast for 2023?

3 Wall Street analysts have issued twelve-month price targets for Humacyte's stock. Their HUMA share price forecasts range from $2.75 to $16.00. On average, they anticipate the company's share price to reach $8.19 in the next twelve months. This suggests a possible upside of 152.7% from the stock's current price.
View analysts price targets for HUMA or view top-rated stocks among Wall Street analysts.

How have HUMA shares performed in 2023?

Humacyte's stock was trading at $2.11 at the beginning of the year. Since then, HUMA stock has increased by 53.6% and is now trading at $3.24.
View the best growth stocks for 2023 here.

When is Humacyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 12th 2023.
View our HUMA earnings forecast.

What ETFs hold Humacyte's stock?

ETFs with the largest weight of Humacyte (NASDAQ:HUMA) stock in their portfolio include Changebridge Capital Long/Short Equity ETF (CBLS).Changebridge Capital Sustainable Equity ETF (CBSE).

What is Humacyte's stock symbol?

Humacyte trades on the NASDAQ under the ticker symbol "HUMA."

Who are Humacyte's major shareholders?

Humacyte's stock is owned by many different institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (0.85%), Charles Schwab Investment Management Inc. (0.39%), LPL Financial LLC (0.28%), Bank of America Corp DE (0.11%), Credit Suisse AG (0.06%) and State of Wisconsin Investment Board (0.05%). Insiders that own company stock include Brady W Dougan, Dale A Sander, Laura E Niklason, Michael T Constantino and William John Scheessele.
View institutional ownership trends.

How do I buy shares of Humacyte?

Shares of HUMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Humacyte's stock price today?

One share of HUMA stock can currently be purchased for approximately $3.24.

How much money does Humacyte make?

Humacyte (NASDAQ:HUMA) has a market capitalization of $334.11 million and generates $1.26 million in revenue each year. The company earns $-26,480,000.00 in net income (profit) each year or ($0.13) on an earnings per share basis.

How many employees does Humacyte have?

The company employs 145 workers across the globe.

How can I contact Humacyte?

Humacyte's mailing address is 1177 AVENUE OF THE AMERICAS 5TH FLOOR, NEW YORK NY, 10036. The official website for the company is www.constellationalpha.com. The company can be reached via phone at 919-313-9633 or via email at investors@humacyte.com.

This page (NASDAQ:HUMA) was last updated on 3/28/2023 by MarketBeat.com Staff